Rosiglitazone maleate side effects

Rosiglitazone maleate is an oral diabetes medicine that helps control blood sugar levels. This medication helps your body respond better to insulin produced by your pancreas. Rosiglitazfone maleate is for people with type 2 diabetes who do not use daily insulin injections. GlaxoSmithKline Plc makes the pharmaceutical drug rosiglitazone maleate.

Side effects of Rosiglitazone maleate
Rosiglitazone maleate can cause an allergic reaction. Allergic rosiglitazone side effects include hives; difficulty breathing; swelling of the face, lips, tongue, or throat.
   Additional rosiglitazone serous side effects include signs of congestive heart failure (swelling or rapid weight gain, shortness of breath, chest pain). Gastrointestinal rosiglitazone side effects include nausea, vomiting, stomach pain, or loss of appetite, and jaundice. other rosiglitazone side effects could include fatigue, hypoglycemia, headache, weakness, sweating, and rapid heart beat. We do not recommend the combination with yohimbe herb since they both have an influence on the heart.

Rosiglitazone side effect - bone loss
Patients taking the diabetes drug rosiglitazone maleate may have an additional side effect - a higher risk of hip and other fractures because the medicine decreases bone formation. A study of 50 postmenopausal women found those on rosiglitazone had a 1.9 percent fall in total hip bone density after 14 weeks of treatment, while those on a placebo experienced a reduction of 0.2 percent. Lumbar spine bone density also fell significantly compared with starting levels but not compared with the placebo. The small New Zealand study comes on the heels of a major clinical trial of rosiglitazone, called ADOPT, reported in December, 2006 which found an unexpected rise in peripheral fractures, most commonly involving the foot and upper limbs. An osteoporosis warning will be added to the drug's label, providing additional ammunition for Merck Inc and Novartis AG as they roll out a new class of diabetes pills known as DPP-IV inhibitors. Merck has Januvia while Galvus is made by Novartis. Rosiglitazone is Glaxo's second-biggest seller, with sales of $2.5 billion in 2005.

Does Rosiglitazone reduce diabetes risk?
Treatment of high-risk patients with the oral antidiabetic drug rosiglitazone may reduce their risk of developing type 2 diabetes by nearly two thirds. In a clinical trial of patients with poor glucose tolerance, 5,269 adults were assigned to receive rosiglitazone or a placebo (sugar pill) daily for an average of 3 years. At follow-up, the subjects in the rosiglitazone group were less likely to develop the disease or die than those in the placebo group, and their risk of progressing to full diabetes was reduced by 60 percent. The rosiglitazone patients were also 70-percent more likely to return to normal blood sugar levels. These patients did, however, have an increased risk of non-fatal heart failure, a condition where the heart muscle is weakened and becomes unable to maintain adequate blood supply to the body's tissues. The researchers, based at McMaster University, Hamilton, Ontario, Canada concluded that for every 1,000 people treated with rosiglitazone for 3 years, about 144 cases of diabetes would be prevented and an extra 4 to 5 cases of heart failure would occur. The Canadian study also looked at the value of a blood pressure drug called ramipril, but found it did not reduce the risk of diabetes or death, although it did help some patients to return to normal blood sugar levels. Ramipril is sold as Altace by King Pharmaceuticals Inc. The study DREAM study (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) was funded by the Canadian Institutes of Health Research, Sanofi-Aventis, GlaxoSmithKline and King Pharmaceuticals. The Lancet, 2006.    
     Comments: Before prescribing rosiglitazone to prevent diabetes, It would be prudent tosee a minimum of a seven year study to determine if rosiglitazone has side effects that we are currently not aware of. It is possible that rosiglitazone could reduce the risk of diabetes, but the cardiac side effects could lead to people on this drug to die sooner. And now we find out that rosiglitazone has side effects involving bone loss and potential osteoporosis.